Novanta Inc. (NOVT) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call indicates positive growth in key segments like Medical Solutions and Automation, with strong bookings and a positive book-to-bill ratio. Despite a decline in operating cash flow, the company shows strong demand and momentum across segments, especially in robotics and automation. The Q&A session reveals strategic positioning in high-growth areas and effective capital deployment plans. The positive sentiment is bolstered by optimistic guidance and strong market demand, suggesting a likely positive stock price movement over the next two weeks.

Key Financial Performance

Fourth Quarter Revenue Record revenue with 9% reported growth, 2% organic growth, and 4% sequential growth. Reasons for growth include strong bookings and performance across all business segments.

Full Year Revenue $981 million, the highest ever for the company. Full year bookings grew 14%. New product revenue grew over 60% for the year, including over 80% growth in the fourth quarter. Growth attributed to commercial excellence and innovation investments.

Adjusted EBITDA (Q4) $61 million, a 17% year-over-year increase, achieving a 23.5% adjusted EBITDA margin. Growth driven by strong bookings and operational performance.

Adjusted Diluted EPS (Q4) $0.91, a 20% year-over-year increase. Growth achieved despite a higher share count from the November equity fundraise.

Adjusted Gross Margin (Q4) 45.5%, down 150 basis points year-over-year and 100 basis points sequentially. Decline due to prioritizing customer deliveries over regional manufacturing transfers, leading to higher dual running costs.

Operating Cash Flow (Q4) $9 million, compared to $62 million in Q4 2024. Decline due to higher inventory builds and temporary account receivable timing items.

Medical Solutions Segment Revenue (Q4) Grew 16% year-over-year. Growth driven by strong demand in Advanced Surgery and new product launches.

Automation Enabling Technologies Segment Revenue (Q4) Grew 2% year-over-year. Bookings up 33% year-over-year, driven by strong demand in robotics and automation applications.

Precision Manufacturing Business Revenue (Q4) Declined 3% year-over-year but grew 8% sequentially. Sequential growth driven by strong activity in target markets.

Robotics and Automation Business Revenue (Q4) Grew 6% year-over-year and 2% sequentially. Growth driven by demand for advanced robotic applications and semiconductor applications.

Precision Medicine Business Revenue (Q4) Grew 16% year-over-year and 4% sequentially. Growth driven by the Keonn acquisition and favorable year-over-year comparables.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

New product revenue: Grew over 60% for the full year and over 80% in Q4, exceeding expectations. This growth is attributed to investments in commercial excellence and innovation.

Next-generation insufflator: Set the industry standard, improving patient safety and surgical workflows. Expected to drive double-digit revenue growth in 2026.

Robotic surgery technologies: Expansion into robotic surgery and arthroscopy is expected to contribute to $400 million in revenue by 2030.

Intelligent laser beam steering subsystems: Launched to meet demand for digital and AI-enabled manufacturing capabilities.

Minimally invasive and robotic surgery: Achieved mid-teens double-digit growth in 2025, with strong momentum expected to continue in 2026.

Robotics and Automation: High single-digit growth expected in 2026, driven by AI-driven warehouse robotics, semiconductor market recovery, and GPU drilling.

Precision manufacturing: Mid-single-digit growth expected in 2026, supported by digitization and automation of manufacturing lines.

Precision medicine: Revenue expected to remain flat in 2026, with investments in RFID solutions and machine vision technologies stabilizing the outlook.

Regional manufacturing initiative: Prioritized customer deliveries over regional manufacturing transfers, leading to temporary higher costs and elevated inventory. Expected to complete transfers by mid-2026.

Novanta growth system (NGS): Embedded as a continuous improvement engine, driving customer success and operational efficiency.

Kaizen events: Over a dozen events across 9 locations focused on commercial excellence, innovation, supply chain optimization, and regionalization.

Acquisition strategy: Raised $600 million in November, with $1.5 billion in acquisition capacity. Focused on medical technologies, consumables, bioprocessing, and embedded software.

Long-term growth strategy: Focused on high-growth markets like AI-driven robotics, minimally invasive surgery, and precision medicine. Targeting mid- to high single-digit organic growth with less cyclicality.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Margins and Cash Flow: Margins and cash flow came in below expectations due to prioritizing customer deliveries over regional manufacturing transfers, leading to higher dual running costs and elevated inventory.

Precision Medicine Business: The business is facing challenges due to life science equipment market dynamics and technology obsolescence cycles, leading to flat sales expectations for 2026.

Regional Manufacturing Transfers: The ongoing regional manufacturing initiative has caused temporary higher costs and inventory levels, impacting gross margins and cash flow.

Operating Cash Flow: Operating cash flow was significantly lower in 2025 compared to 2024, impacted by regional manufacturing dynamics, higher inventory builds, and temporary account receivable timing issues.

Stock Compensation Expense: Higher stock compensation expenses in the first half of 2026 due to a one-time 2025 all-employee equity grant, impacting earnings per share.

Debt and Equity Fundraise: The November equity fundraise increased the share count, diluting earnings per share, although it reduced debt and interest expenses.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Revenue Growth: For 2026, Novanta expects GAAP revenue to be approximately $1,030 million to $1,050 million, representing 4% to 6% organic revenue growth. Sequentially increasing momentum in quarterly organic growth is anticipated, with Q1 organic growth projected at 1% to 3% and Q2 at 5% to 7%.

Gross Margin Expansion: The company targets a full-year adjusted gross margin of approximately 47% in 2026, reflecting a 100 basis point expansion year-over-year. This improvement is attributed to the completion of regional manufacturing production moves by Q2 2026.

Adjusted EBITDA: For 2026, adjusted EBITDA is expected to be between $245 million and $250 million, representing a low double-digit increase year-over-year, with an adjusted EBITDA margin of approximately 24%.

Earnings Per Share (EPS): Adjusted diluted EPS for 2026 is projected to range between $3.50 and $3.65, reflecting growth of up to 11% year-over-year. This includes impacts from the equity fundraise and stock compensation expenses.

Operating Cash Flow: Operating cash flow for 2026 is expected to range between $145 million and $185 million, more than doubling the 2025 result. Strong cash flow materialization is anticipated after the completion of regionalization site initiatives in Q2 2026.

Segment Growth Projections: - Automation Enabling Technologies: Low to mid-single-digit growth in Q1 2026, with full-year growth supported by bookings and backlog.

Medical Solutions: High single-digit to low double-digit reported growth in Q1 2026, with strong full-year growth driven by new product launches and procedural growth.
Robotics and Automation: High single-digit growth in 2026, supported by AI-driven tailwinds, semiconductor market recovery, and GPU drilling opportunities.
Precision Manufacturing: Mid-single-digit growth in 2026, driven by digitization and automation of manufacturing lines.
Precision Medicine: Flat sales in 2026, with stabilization supported by investments in RFID solutions and machine vision technologies.

Acquisition Strategy: Novanta has nearly $1.5 billion in acquisition capacity and plans to deploy meaningful capital in 2026, focusing on medical technologies, medical consumables, bioprocessing, and embedded software.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

Share Repurchase Program: In the fourth quarter, we repurchased $19 million worth of company stock. For the full year, we repurchased nearly $40 million of shares. While acquisitions remain our top capital allocation priority, we'll still repurchase shares under our approved repurchase program when the value of purchasing the stock gives us a greater cash return versus the intrinsic future value of Novanta.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:What businesses and product categories are driving the $30 million sequential increase in bookings in the Automation Enabling Technologies segment?

A:The increase is broad-based across all businesses, including Medical Solutions, with double-digit bookings growth and a positive book-to-bill ratio. Key drivers include robotics and automation (precision robotics for warehouse automation, surgical robotics, humanoids), semiconductor capital equipment market improvement, and strong momentum in GPU board drilling for AI. Precision manufacturing also contributed with factors like customer destocking subsiding, strong design win performance, and intelligent subsystems of laser beam steering gaining traction.

Q:What is the update on the industrial robotics order announced earlier, and any revenue expectations for 2026?

A:The momentum is building steadily, with a modest ramp this year and sequential growth expected. The order highlights the company's technology leadership and creates opportunities in precision robotics applications like surgical robotics, warehouse automation, and humanoids. The company is well-positioned with superior technology in servo drives and force/torque technology for humanoids and warehouse automation.

Q:How does the company reconcile strong top-line momentum with the expectation of about 9% EPS growth?

A:The EPS growth is impacted by a $0.22-$0.24 headwind from a fundraise and a 14% headwind from an all-employee equity grant, both of which are temporary. Despite these, the organic EPS growth is much higher, and the company plans to deploy the raised capital for acquisitions to generate income.

Q:What is the significance of the GPU Boards opportunity, and how does it impact the air bearing spindle business?

A:The GPU Boards opportunity is significant due to the increasing demand for drilling thick and tough boards for Gen AI and GPU applications, which require the company's spindles for precision and throughput. This has revived the air bearing spindle business, creating a multi-year growth trajectory. The opportunity involves new end users while maintaining strong relationships with existing OEM customers.

Q:Was the book-to-bill ratio positive across all businesses and segments?

A:Yes, the book-to-bill ratio was positive across all four business units and the two segments, indicating strong momentum, building backlog, and double-digit bookings growth in each business unit.

Q:What are the company's priorities and filtering process for M&A, and how does it ensure protection and moat around acquisitions?

A:The company prioritizes medical, consumables, and embedded software businesses with high growth potential, strong gross margins, and high cash conversion. It focuses on businesses that exceed cost of capital by year 2 (for bolt-ons) or year 5 (for larger deals). The company ensures acquisitions have strong customer relationships, regulatory and quality performance, and proprietary know-how to maintain a competitive moat.

Q:What is the contribution of the Keonn acquisition in the first quarter, and what is its strategic significance?

A:The Keonn acquisition contributed about $9 million in incremental revenue in the first quarter. It has a mix of project-based and recurring revenue streams, with strategic significance in retail and potential applications in the hospital environment. The company is also exploring opportunities in the medical field through a minority investment in a similar business in Spain.

Q:Review of Unclear Management Responses

A:Management avoided providing specific revenue expectations for the industrial robotics order in 2026, using general terms like 'modest ramp' and 'sequential growth.' Additionally, while discussing the M&A pipeline, they did not provide detailed valuation metrics or specific targets, focusing instead on general strategic priorities and filtering processes.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

NOVT Transcript

Novanta Inc. (NOVT) Q4 2025 Earnings Call Transcript

Positive2-24

Novanta Inc. (NOVT) Q3 2025 Earnings Call Transcript

Positive11-4

The earnings call highlights strong new product revenue growth, improved customer bookings, and positive adjusted financial metrics despite temporary cash flow issues. The Q&A section reveals optimism about future growth in robotics and automation, with significant opportunities in the physical AI market. Margins are expected to improve with regional manufacturing strategies. While there are some concerns about specific segments, overall, the company's strategic initiatives and growth prospects suggest a positive stock price reaction.

Novanta Inc. (NOVT) Q2 2025 Earnings Call Transcript

Unknown8-5

The earnings call presents a mixed picture. While there are positive aspects such as strong bookings growth, advanced surgery business growth, and promising new product launches, there are concerns with the decline in precision medicine sales and uncertain life sciences outlook. The Q&A reveals cautious guidance and unresolved tariff issues. The positive impact of the Kion acquisition and potential growth in warehouse robotics is offset by uncertainties in organic growth and market recovery, leading to a neutral stock price prediction.

Novanta Inc. (NOVT) Q1 2025 Earnings Call Transcript

Unknown5-6

The earnings call presents mixed signals: steady financial performance with flat growth, but challenges include trade disruptions and NIH funding cuts. Positive aspects like new product launches and cost savings are offset by revenue deferrals and market volatility. The Q&A reveals management's cautious optimism, but lack of precise guidance on acquisitions and NIH exposure creates uncertainty. Given these factors, the stock is likely to remain stable, with minor fluctuations.

NOVT Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.